Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. METHODS: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review. RESULTS: The 108 patients with triple-negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression-free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7). CONCLUSIONS: Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall response rate was 33.3% (95% CI 24.6-43.1), with a median duration of response of 7.7 months (95% CI 4.9-10.8).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
In the citing paper
“Of the patients with a response to sacituzumab govitecan-hziy, 55.6% maintained their response for ≥6 months and 16.7% maintained their response for ≥12 months.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationKohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citation
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 · DOI · Paper page
Cited by
Items 601–700 of 874
Wang, D., Zhang, L., Wang, B., Zhao, L., Deng, L., Xu, W., & Huang, H. (2023) · Protein Expression and Purification · doi:10.1016/j.pep.2023.106242 · Cited by 5
Malhotra, S., & Tadros, A. B. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.01.009 · Cited by 7
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer
Oh, S. Y., Rahman, S., & Sparano, J. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1876662 · Cited by 7
“0 months [120] The confirmatory phase 3 ASCENT study”
BackgroundMarhold, M. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00781-7 · Cited by 6
Liu, J., Guo, L., Rao, Y., Zheng, W., Gao, D., Zhang, J., Luo, L., Kuang, X., Sukumar, S. V., Tu, Y., et al. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s367121 · Cited by 5
“However, it is only used as the third or later line of treatment.(35) Chemotherapy is still the primary systemic adjuvant therapy for TNBC patients.”
MethodRetractedTriple negative breast cancer: any closer to cracking the code?
Peddi, P. F. (2021) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000769 · Cited by 10
Oluwalana, D., Adeleye, K. L., Krutilina, R. I., Chen, H., Playa, H. C., Deng, S., Parke, D. N., Abernathy, J., Middleton, L., Cullom, A., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217011 · Cited by 4
Antibody–drug conjugates in breast cancer
Zhu, Y., Song, Y., Zhou, X., Zhang, W., & Luo, H. (2025) · Carcinogenesis · doi:10.1093/carcin/bgae082 · Cited by 4
A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan
Ito, T., Tanaka, Y., Ogata, D., Nishida, H., Shiomi, T., TANAKA, R., Kawaguchi, A., Miyashita, A., Fukushima, S., Shojiguchi, N., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84566-y · Cited by 5
Antibody–drug conjugates in urothelial carcinoma: current status and future
Ruder, S. F., Martinez, J., Palmer, J. S., Arham, A. B., & Tagawa, S. T. (2025) · Current Opinion in Urology · doi:10.1097/mou.0000000000001263 · Cited by 5
Nevala, W. K., Geng, L., Xie, H., Stueven, N. A., & Markovic, S. N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073295 · Cited by 8
“Additionally, an ADC containing SN-38 covalently linked to anti-TROP2, IMMU-132, has also been FDA approved for relapsed and refractory TNBC [9]; therefore, our NIC containing PTX or SN-38 bound to anti-PD-L1 is a logical option for TNBC treatment as suggested by our in vivo results (Figure 4).”
Firouzjaei, A. A., & Mohammadi‐Yeganeh, S. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400969 · Cited by 4
Lan, M., Meng, F., Gao, L., Giri, A. K., Nishikawa, M., Kusamori, K., Lee, J., Asim, M. H., Arshad, S., Gu, H., et al. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214464 · Cited by 4
Combine mitochondrial-targeted gene therapy and chemotherapy to treat triple-negative breast cancer
Varadkar, T., Zhou, Z. “., Zhang, J., Sarkar, A., Du, Z., Chowdhury, S., Lim, H., Zhou, L., & Liu, X. M. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03572-8 · Cited by 5
Shaaban, A. E., Jourdain, H., Desplas, D., Vignot, S., Zureik, M., & Haddy, N. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03346-9 · Cited by 5
Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review
Zhou, J., Wang, H., Xie, H., Xu, X., & Xiao, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1698458 · Cited by 4
Anaganti, S., Bhujade, A., Murkli, S. L., Sparta, Z., Panth, N., Weig, A. W., Vartak, R., Ponte, J. F., Dugal‐Tessier, J., & Jain, N. F. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01465-3 · Cited by 4
“In contrast, sacituzumab govitecan (Trodelvy ® ), which alsoemploysthetopoisomeraseIinhibitorSN-38,hasshownrobustef fi cacy across multiple solid tumors with no clinically signi fi cant ILD reported 9,10 .”
Morse, W., Nawaz, H., & Choudhry, A. A. (2023) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-022-00159-8 · Cited by 4
“5 months, that sheds light upon the clinical task, and absence of cross resistance with anti-body drug conjugate [13] (refer to evidence table in Supplementary information).”
BackgroundMethodInfluentialSchlam, I. M., Tolaney, S. M., & Tarantino, P. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2171993 · Cited by 5
“For patients with HER2-low expression, after at least one line of chemotherapy, T-DXd or sacituzumab govitecan should be considered; while those with HER2-zero tumors could be treated with sacituzumab govitecan followed by other lines of chemotherapy and consideration for clinical trials [12,52].”
Self-citationMatossian, M. D., Chen, N., & Nanda, R. (2023) · Current Breast Cancer Reports · doi:10.1007/s12609-023-00492-4 · Cited by 4
Cheng, S.-X., Chen, Q., Lin, G., Han, Y., Wang, B., Dai, Y., & Zhao, Y. (2023) · Medicine · doi:10.1097/md.0000000000034486 · Cited by 4
Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?
Lønning, P. E. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.11.010 · Cited by 4
Rebecca Tombleson, P. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88627 · Cited by 4
A narrative review of biomarkers in advanced triple negative breast cancer
Chehade, R., Awan, A. A., & Fernandes, R. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-20-76 · Cited by 7
“ADCs include three agents: an antibody directed to a tumor antigen, a cytotoxic molecule, and a linker in between (14).”
BackgroundInfluentialAntibody-drug conjugates in treating older patients suffering from cancer: what is the real value?
Perego, G., Ghidini, A., Luciani, A., & Petrelli, F. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1999711 · Cited by 4
Ghafouri, S. R., Guvvala, S. L., Jones, C., & Philipovskiy, A. V. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002298 · Cited by 4
Lofgren, K. A., Reker, N. C., Sreekumar, S., & Kenny, P. A. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac020 · Cited by 4
“Similarly, TROP2 is expressed in skin, uterus, bladder, oral mucosa, nasopharynx and lungs [16], yet sacituzumab govitecan, an SN38 conjugate, is approved for triple-negative breast cancer [17].”
BackgroundCurrent and Emerging Role of Antibody–Drug Conjugates in HER2-Negative Breast Cancer
Abelman, R. O., Keenan, J. C., Ryan, P. K., Spring, L. M., & Bardia, A. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.08.015 · Cited by 5
Self-citationPassalacqua, M. I., Rizzo, G., Santarpía, M., & Curigliano, G. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159805 · Cited by 4
“5 and 13 months, respectively [198], FDA granted accelerated”
BackgroundInvestigational antibody-drug conjugates in clinical trials for the treatment of breast cancer
Okines, A. F. C., & Ulrich, L. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1940950 · Cited by 4
Gong, X., Gu, L., Yang, D., He, Y., Li, Q., Qin, H., & Wang, Y. (2024) · eLife · doi:10.7554/elife.100923.3 · Cited by 4
TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity
Liu, Q., Chung, S., Murata, M. M., Han, B., Gao, B., Zhang, M., Lee, T.-Y., Chirshev, E., Unternaehrer, J., Tanaka, H., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70583 · Cited by 3
“It showed a 35% response rate in patients with relapsed or refractory metastatic TNBC compared to the 5% response rate of chemotherapy [9, 10].”
ResultQureshi, Z. A., Jamil, A. R., Altaf, F., Siddique, R., Fatima, E., Dost, S., Zelkowitz, R., & Shah, S. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002347 · Cited by 3
“The clinical bene fi t rate was 45.4%, median progression-free survival was 5.5 months, and overall survival was 13 months [7,17] .”
BackgroundMethodInfluentialHe, L., Wang, Y., Curry, J. L., Ning, J., Aung, P. P., Nagarajan, P., Prieto, V. G., Torres-Cabala, C. A., & Cho, W. C. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.105853 · Cited by 3
[89Zr]Zr-DFO-Trodelvy immunoPET for noninvasive Trop2 imaging in bladder cancer
Huang, W. (2025) · American Journal of Nuclear Medicine and Molecular Imaging · doi:10.62347/kkee6954 · Cited by 3
Pieniążek, M., Kubeczko, M., Las‐Jankowska, M., Polakiewicz-Gilowska, A., Łacko, A., Jarząb, M., Bielčiková, Z., Pacholczak‐Madej, R., & Püsküllüoğlu, M. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04823-3 · Cited by 6
Tünbekici, S., Şahin, G., Ön, S., Oruç, A. F., Eryılmaz, M. K., Sakin, A., Coşkun, A., Seyyar, M., Uzundere, F. K., Kolemen, E., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70213 · Cited by 3
Huang, W., Chao, F., Li, R., Yang, Y., Hsu, J. C., DeLuca, M. C., Engle, J. W., Han, X., Kang, L., & Cai, W. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01223 · Cited by 3
Xie, G., Chen, G., Lv, W., Tai, W., Zhang, B., & Zhou, X. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01845-6 · Cited by 3
“It has been successfully used to treat TNBC and mUC, validating TROP2 as an effective therapeutic target in oncology [46–51].”
Xu, Y.-X., Shen, Q., Lu, X.-F., Shen, X.-L., Zhang, L., Qiao, X.-W., & Zhang, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1714638 · Cited by 5
Rugo, H. S., Tolaney, S. M., Cortés, J., Marmé, F., de Azambuja, E., Xu, B., Sohn, J., Naito, Y., Valdez, T., Gary, D., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.106905 · Cited by 3
“10,11,13,14,26,27 Patients included in the analysis were those with HER2-negative mBC, including mTNBC and HR-positive/HER2-negative mBC, who received SG (10 mg/kg intravenously, days 1 and 8 of every 21-day cycle).”
Self-citationJia, W., Yan, T., An, S., Zhang, Y., Wu, Q., Wu, Z., Xu, D., Hu, Z., Wang, C., Huang, G., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271093 · Cited by 3
“…clinical trials have demonstrated that sacituzumab govitecan signi fi cantly improves progression-free survival and overall survival in patients with metastatic TNBC and HR-positive/HER2-negative breast cancer ( 7 – 9 ), establishing it as a cornerstone of clinical management for these sub-types.”
Mansinho, A., Albuquerque, J., Lopes, A., & Calvo, E. (2026) · Cancer · doi:10.1002/cncr.70416 · Cited by 3
Li, R., Chen, X., Huang, Q., Ling, H.-J., Gong, K., & Chen, Z. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218753 · Cited by 3
Current and future therapies for triple-negative breast cancer
Wang, Z.-X., Liu, X., Wu, Y., Xiao, Y.-L., Ge, L., Wu, S., Jiang, Y., & Shao, Z.-M. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01839-x · Cited by 3
Kabirian, R., & Silva, A. D. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.12.010 · Cited by 3
Debnath, U., Verma, S. K., Patra, J., & Mandal, S. K. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132524 · Cited by 3
Chen, X., Zhang, J., Jiang, L., & Yan, F. (2022) · Statistical Methods in Medical Research · doi:10.1177/09622802221129049 · Cited by 3
“Metrics for evaluating operating characteristics include (1) Percentage of correctly selecting OBD (PCS); (2) Percentage of selecting unacceptable doses as OBD (PSU); (3) Percentage of patients treated at OBD (% Patients at OBD); (4) Percentage of patients treated at overdoses (% Patients at overdoses); (5) Expected s…”
BackgroundYaringaño, J., Roca-Herrera, M., Eremiev, S., Baselga, P. M., Benito, P., Núñez-Marín, F., Benavente, S., & Pimentel, I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1378248 · Cited by 3
Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis
Guarin, G., Netzel, A., Flores, K. M., Čumpelik, A., & Bose, R. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03828-z · Cited by 3
Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments
Belluzzi, L., Martinelli, G., Medici, B., Farina, A., Martinelli, E., Canino, F., Caggia, F., Molinaro, A., Barbolini, M., Tamburrano, F., et al. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s489419 · Cited by 5
Lyu, H., Zhou, T., Sun, X., Chen, H., Li, J., Shao, M., Li, J., Zhang, Q., Jiang, G., & Zhou, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-91318-z · Cited by 3
“Of particular interest, triple-negative breast cancer, renowned for its aggressive nature 30 , exhibited significantly higher EPHB6 expression than other breast cancer types, suggesting that increased EPHB6 expression in breast cancer might correlate with enhanced invasiveness.”
Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids
Wu, Y., Pi, H., He, X., & Sheng, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1629690 · Cited by 4
“…for treating the adults with unresectable locally advanced or metastatic, hormone receptor-positive/HER 2-negative breast cancer (13), and speedily approved for the adults with metastatic tiple-negative breast cancer who previously received at least two therapies for metastatic diseases (14, 15).”
Katoh, M., & Katoh, M. (2021) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2021.720577 · Cited by 3
“2 and NECTIN4) and miscellaneous transmembrane proteins (SLC39A6/LIV1 and TROP2) have been targeted using antibody-based biologics (Andrews et al., 2019; Bardia et al., 2019; Katoh and Katoh, 2020; Powles et al., 2021).”
BackgroundChemistries and applications of DNA-natural product conjugate
Chen, Y., Li, W., & Xing, H. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.984916 · Cited by 3
“To alleviate the drawbacks of natural products, a variety of conjugation technologies integrating the natural product with another functional motif have been developed, including smallmolecule drug conjugate (Krall et al., 2014; Zhuang et al., 2019), peptide drug conjugate (Ma et al., 2017; Wang et al., 2017), protein…”
Theranostics of triple negative breast cancer: a review
Molchanov, O., Maystrenko, D. N., & Stanzhevskii, A. A. (2023) · Diagnostic radiology and radiotherapy · doi:10.22328/2079-5343-2023-14-2-15-30 · Cited by 3
Synthèse des profils de toxicité des anticorps drogue-conjugués dans le cancer du sein
Collineau, B., Gonçalvès, A., Bertucci, F., & de Nonneville, A. T. (2024) · Bulletin du Cancer · doi:10.1016/j.bulcan.2024.04.004 · Cited by 5
Feith, M., Sajib, S. D., Myrann, A. G., Høgset, A., Garrido, P., Martínez, A., Knutsen, E., Sandvig, K., Skotland, T., Mælandsmo, G. M., et al. (2025) · Advanced NanoBiomed Research · doi:10.1002/anbr.202400208 · Cited by 3
Masterson, T. A., & Tagawa, S. T. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.05.021 · Cited by 3
Ding, X., & Chen, L. (2022) · Computational Intelligence and Neuroscience · doi:10.1155/2022/3054587 · Cited by 6
“Literature [11] believes that negative life events, social support, depression, and other psychosocial factors have a greater impact on the immune function of cancer patients.”
BackgroundBiomarkers and potential targets for immune and cellular therapy in triple negative breast cancer
Molchanov, O., Maistrenko, D. N., Granov, D. A., Vasina, L. V., Popova, A., Vasilevskaya, I. A., Mikolaichuk, O. V., Сергеевна, Ш. О., Popova, Е. А., Protas, A. V., et al. (2022) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2022-11-2-16-30 · Cited by 3
Sacituzumab govitecan — a new therapy for patients with triple-negative breast cancer
Pogoda, K., Jagiełło-Gruszfeld, A., Niwińska, A., & Nowecki, Z. I. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2022.0003 · Cited by 3
“TNBC IMMU-132-01 [15] SG 108 33% (3% CR and”
BackgroundMethodInfluentialRole of TROP 2 overexpression in selected solid tumors
Chmielewska, A., & Kubiatowski, T. (2023) · Oncology in Clinical Practice · doi:10.5603/ocp.2023.0017 · Cited by 3
Last but not least: antibody–drug conjugates in hormone receptor-positive metastatic breast cancer
Stecklein, S. R., & Sharma, P. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.001 · Cited by 3
Advances in PET/CT Imaging for Breast Cancer Patients and Beyond
Khalil, D., Lotfalla, A., Girard, A., Ha, R. S., Dercle, L., & Seban, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020651 · Cited by 3
“New therapeutic molecules, as well as antibody–drug conjugates (trastuzumab–deruxtecan and sacituzumab govitecan for example) [5,6] or molecule combinations (chemo-immunotherapy for example) [7–9], have revolutionized the management of metastatic breast cancer patients, whose prognosis is among the poorest.”
BackgroundLiu, Y., Duan, X., Wu, S., Liu, X., Fan, H., Zhang, D., Wu, X., & Hua, P. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2430305 · Cited by 2
“During a phase I/II multicenter trial, only 3% of patients discontinued treatment due to adverse effects, and 4% of patient deaths during the treat-ment were attributed to disease progression [12,13].”
Staquicini, F. I., Tang, F. H. F., de Oliveira, V., Kim, S. Y., Chen, E. R., Markosian, C., Staquicini, D. I., Wu, Y., Parsons, J. K., Barnhart, K. F., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188492 · Cited by 2
“…found EphA5 is also expressed in several other human solid tumors, including 84% of breast (estro-gen-receptor-positive, n = 23 of 26 [88%]; triple-negative breast cancer [TNBC], n = 18 of 23 [78%]), 70% of gastric ( n = 7 of 10), and 68% of colon ( n = 15 of 22) cancers, among others (Figure 1).”
Hormone Receptor and HER2 Testing in Breast Cancer
Solarewicz, J., & Allison, K. H. (2025) · Surgical pathology clinics · doi:10.1016/j.path.2025.07.004 · Cited by 2
Lin, S.-Y., Chang, C.-T., Wu, R., Lai, C., & Chen, Y. (2025) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2025.101951 · Cited by 2
“Nectin-4 is targeted by enfortumab vedotin, which is approved for advanced urothelial carcinoma, while TROP2 is targeted by sacituzumab govitecan, approved for metastatic triple-negative breast cancer (Rosenberg et al., 2019; Bardia et al., 2019).”
Ferrao, R., Zhang, J., Chou, C.-C., Nieto, A., Langeslay, D. J., Chatterjee, M., Jin, D., Hung, M., Scott, I., Nagel, M., et al. (2025) · Structure · doi:10.1016/j.str.2025.11.002 · Cited by 4
Sinanian, M. M., Chakraborty, E., Elshazly, A. M., Azzam, S., Nassif, N., & Gewirtz, D. A. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl39310 · Cited by 2
“…such as SG are not only capable of killing antigen-expressing cells following internalization, but also eliminate adjacent tumor cells that do not express the target antigen by releasing the drug in the tumor microenvironment due to its cleavable linker (often termed a bystander effect) [12–15].”
InfluentialZeng, T., Li, B., Xu, J., Sun, Y., Xiao, Y., Zhou, Z., Hua, Y., Wu, S., Shi, H., Li, G., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c06259 · Cited by 2
Liang, S., Liao, W., Jiang, J., Bao, Y., & Zheng, H. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03949-w · Cited by 2
Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer
Tan, Y., Zeng, C., Wang, J., & Ma, F. (2026) · Cancer Innovation · doi:10.1002/cai2.70043 · Cited by 6
“For example, SG and datopotamab deruxtecan (Dato‐DXd) have been shown to elicit this bystander effect, displaying promising clinical efficacy across a spectrum of solid tumours in clinical trials [111–114].”
Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate
Skafte, A., Vidal-Calvo, E. E., Choudhary, S., Mujollari, J., Dagil, R., Martin-Salazar, A., Oo, H. Z., Duvnjak, L., Theander, T. G., Daugaard, M., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08420-x · Cited by 3
Febriana, R. A., Novitasari, D., Ikram, N. K. K., & Muchtaridi, M. (2026) · Future Science OA · doi:10.1080/20565623.2025.2582450 · Cited by 3
“Recently, the antibody-drug conjugate sacituzumab govitecan has been introduced as a treatment for patients with advanced or recurrent tNBc [10,11], offering a new therapeutic option for difficult-to-treat cases.”
Median, D., Antone, N. Z., Volovăț, S. R., Mazilu, L., Negru, S. M., Curca, R. O., Nita, A. L., Pătru, R. I., Ungureanu, A., Lupu, V., et al. (2026) · Current Oncology · doi:10.3390/curroncol33020120 · Cited by 3
“- IMMU-132-01: Response rate to SG was 34.3% and median duration of response was 9.1 months in patients with refractory mTNBC as assessed by an independent central review committee; median PFS was 5.5 months, and OS was 13.0 months [40].”
InfluentialJanicki, P., Makowska, A. M., Jakubczyk-Słabicka, A., Zaucha, R., Barańska‐Rybak, W., Owczarek, W., & Górska‐Ponikowska, M. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01693-2 · Cited by 2
Bibliometric analysis of genetically engineered bacteria in tumor therapy
Zhu, Y., Yin, Y., Li, Y., Wang, Q., Chen, Y., Gu, K., Yang, R., Zhou, M., & Chen, D. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1794032 · Cited by 3
Zhao, H., Zhang, S., Wang, F., Yu, P., Li, J., Jia, L., He, P., Liu, R., Zhang, J., Wang, K., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1828131 · Cited by 3
“Currently approved for breast and urothelial carcinomas (57 – 59), SG was evaluated in the single-arm, basket Phase II TROPiCS-03 study (NCT03964727) based on TROP-2 overexpression in HNSCC and the unmet need following platinum and PD-1 blockade failure.”
Weiss, J. A., Nicklawsky, A., Kagihara, J. A., Gao, D., Fisher, C. M., ELIAS, A. D., Borges, V. F., Kabos, P., Davis, S. L., Leong, S., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3487 · Cited by 2
Self-citationRygiel, K. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00066 · Cited by 2
“, atezolizumab-anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody, and pembrolizumab—anti-programmed cell death protein-1 (PD-1) monoclonal antibody], and a combination of a monoclonal antibody targeting trophoblast cell-surface antigen 2 (Trop-2) with SN-38 (sacituzumab govitecan-hziy, an antibody-drug c…”
BackgroundSun, Z., Liu, C., Yao, Y., Gao, C., Li, H., Wang, L., Li, Y., & Sun, C. (2025) · Medicine · doi:10.1097/md.0000000000041739 · Cited by 2
“Papers published in the New England Journal of Medicine between 2019 and 2024 mainly focused on the long-term outcomes of ICB intervention at different stages of TNBC, the combination of ICB with other therapies, and the application of ICB drug conjugates in metastatic TNBC. [12,53,54]”
Iyer, K. A., Tenchov, R., Ivanov, J. M., & Zhou, Q. A. (2025) · ACS Omega · doi:10.1021/acsomega.5c00693 · Cited by 2
Cáncer de mama triple negativo: terapias sistémicas actuales y experiencia local
Sulbaran, G. C. L., Walbaum, B., Appuhn, M. C., Francisco Domínguez, C., Lara, T. M., Francisco Acevedo, C., & Rojel, C. G. S. (2021) · Revista de Cirugía · doi:10.35687/s2452-45492021003942 · Cited by 2
Chang, Q., Fan, L., Li, M., & Liu, L. (2023) · Medicine · doi:10.1097/md.0000000000033059 · Cited by 2
“…the TROP2 anti-body-drug conjugate sacituzumab (Trodelvy), conjugated to the chemotherapeutic SN-38, has already been FDA-approved for TNBC. [12,13] Although immunotherapy is considered the most promising treatment for TNBC, [14,15] most TNBC patients fail to respond to T cell-mediated…”
BackgroundGuerra, E., Trerotola, M., Relli, V., Lattanzio, R., Boujnah, K., Travali, N., Moschella, A., Todaro, P., Pierdomenico, L., Pietro, R. D., et al. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2023.1297367 · Cited by 2
“The Sacituzumab govitecan (TRODELVY, IMMU-132) antibody-drug conjugate (ADC) has been approved by the FDA for therapy of patients with metastatic estrogen receptor-positive and triple-negative breast cancer (Bardia et al., 2019; Bardia et al., 2021) and urothelial carcinomas (Tagawa et al., 2021).”
BackgroundNovel therapeutic strategies for patients with metastatic triple-negative breast cancer
Петровна, Г. И., Гордеева, О. О., & Manukyan, M. S. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2020.4.200495 · Cited by 3
Quantitative Determination of Intracellular Bond Cleavage
Walker, J. A., Sorkin, M. R., & Alabi, C. A. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1250-7_14 · Cited by 2
ADC Linkers Strategies for the Release of Alcohol-containing Payloads
Miller, J. T. G., & Tumey, L. N. (2021) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165153-00232 · Cited by 3
Research Progress of Antibody-Drug Conjugate
李, 玲. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.119603 · Cited by 2
Toripalimab: a new torchlight illuminating the path for metastatic triple negative breast cancer?
Park, S., & Ahn, S. G. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-4 · Cited by 2
Agarwal, P. K., Sfakianos, J. P., Feldman, A. S., Tagawa, S. T., & Black, P. C. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.05.036 · Cited by 1
Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer
Vidula, N., Rodriguez, K., Wong, A. K., & Boyraz, B. (2024) · New England Journal of Medicine · doi:10.1056/nejmcpc2309499 · Cited by 2
Exploring the Role of PROTACs for the Treatment of Breast Cancer
Pannu, A. S., Goyal, R. K., & Goswami, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_12 · Cited by 1
Alrosan, A. Z., Dmour, I. M., Rataan, A. O., Heilat, G. B., & Alrosan, K. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102054 · Cited by 2
“This wider range is consistent with SACITUZUMAB GOVITECAN-HZIY ’ s mechanism, which targets Trop-2 (highly expressed in TNBC but also present on some normal epithelial cells) and delivers the potent SN-38 payload, impacting various rapidly dividing normal cells (Aditya [6, 26]).”
Hyaluronic Acid Conjugated Geraniol for Targeted Breast Cancer Therapy
Yu, H., Jiang, L., Bai, Y., Wu, J., Ning, N., Duan, S., & Zhao, Y. (2025) · Natural Product Communications · doi:10.1177/1934578x251344985 · Cited by 1
Current Approaches of Nuclear Molecular Imaging in Breast Cancer
Schäfer, L., Altunay, B., Heesch, A., van Nijnatten, T. J. A., Vaz, S. C., Juweid, M. E., & Mottaghy, F. M. (2025) · Cancers · doi:10.3390/cancers17132105 · Cited by 3
“While it is present in numerous normal tissues, TROP2 is notably upregulated in various cancers including BCa [131,132].”
Zhu, Y., Zhang, Z.-B., Dai, X., Liu, W., Sun, J., Liu, J., Zhao, Y., Ren, W., Pan, C., Zhou, Z., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.031 · Cited by 2
“However, despite their potent antitumor effects in breast, pancreatic, liver, and colon cancers, the underlying mechanisms of action are still unclear, which limits their clinical applications 48,50 .”
Antibody–Drug Conjugates: The Past, Present and Future
Phillips, G. D. L. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070524-032954 · Cited by 2
Metadata
- Authors
- Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., Shah, N. C., Rugo, H. S., Goldenberg, D. M., Sweidan, A. M., Iannone, R., Washkowitz, S., Sharkey, R. M., Wegener, W. A., & Kalinsky, K.
- Affiliations
- Harvard University (US)
- Vanderbilt University (US)
- Cornell University (US)
- Orlando Health (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 741-751
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2917403028
- Cited by
- 874
- References
- 37
- Citations by year
- 2026: 76 · 2025: 103 · 2024: 111 · 2023: 125 · 2022: 167 · 2021: 167 · 2020: 91 · 2019: 32
- FWCI
- 36.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Immunomedics Inc
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- sacituzumab govitecan, antibody-drug conjugates, metastatic triple-negative breast cancer, TROP2, SN-38, refractory disease, objective response rate, duration of response, progression-free survival, overall survival, safety, febrile neutropenia, anemia, neutropenia
- MeSH terms
- Irinotecan, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anemia, Antigens, Neoplasm, Antineoplastic Agents, Camptothecin, Diarrhea, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Cell Adhesion Molecules, Survival Rate, Immunoconjugates, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.